News

Replimune Stock Plummets 75% After FDA Rejects Application for Skin Cancer Treatment
Replimune said the agency had issued a complete response letter regarding the company’s biologics license application for RP1 ...
TipRanks on MSN4d
Why Is Replimune Stock (REPL) Down 75% Today?
Replimune (REPL) stock plummeted on Tuesday after the biotechnology company received a Complete Response Letter (CRL) from ...
Replimune: A Surprise CRL Exposes Fragility Of The Melanoma Program
Replimune Group, Inc. faces FDA setbacks with RP1, raising financial risks and dilution concerns. Click here to find out why ...
Replimune rebounds despite analyst downgrades on FDA rejection
Replimune (REPL) stock rebounds even as FDA rejection of its RP1 skin cancer drug lead to multiple analyst downgrades on Wall Street. Read more here.
BioSpace4d
Replimmune Plummets Following FDA’s Surprise Rejection of Melanoma Treatment
BMO Capital Markets pointed to FDA leadership, and CBER Director Vinay Prasad in particular, as potential factors in the ...
FDA Rejects Replimune's Blood Cancer Drug, Stock Sinks
Replimune stock fell after the FDA rejected its RP1 application, citing flaws in the trial design and lack of substantial evidence for approval.
TMCnet3d
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Replimune Group, Inc. ("Replimune" or "the Company") (NASDAQ: REPL) for ...